Risperdal® is an antipsychotic drug prescribed to treat certain mental and mood disorders, such as schizophrenia, bipolar disorder, and irritability associated with autism. Research has shown that Risperdal can cause gynecomastia—the development of abnormally large male breasts—in young boys and adolescents, which often requires surgery to correct.
Along with the development of abnormally large male breasts, lactation may occur
If you or your son took Risperdal and suffered from gynecomastia or lactation, you may be entitled to compensation for medical bills, pain and suffering, and other expenses. Contact Cory Watson Attorneys 24/7 to find out if you have a claim for a Risperdal lawsuit—just dial (877) 562-0000 or complete a free initial consultation form.
Risperdal® Gynecomastia Risk
In January 2012, Bloomberg reported that Johnson & Johnson, the manufacturer of Risperdal, was marketing the drug to doctors working with troubled children for uses not approved by the FDA in 2004.
Research has shown the risks Risperdal can pose to children. The largest study on the side effects of the drug in adolescents and children showed hormonal changes in male patients that led to the development of abnormally large male breasts, or gynecomastia. Researchers concluded that Risperdal should be administered to children and adolescents with caution.
Get Help With Your Risperdal® Injury Lawsuit
Cory Watson Attorneys wants to help if you or your son took Risperdal before October of 2006 and suffered from gynecomastia or developed lactation. Our lawyers have recovered more than $2 billion nationwide, and we’re ready to help you and your family get the money you deserve for your medical bills, lost wages, and pain and suffering.
Call (877) 562-0000 or complete a free initial consultation form for a confidential case review. The conversation takes just minutes—and it may help protect your rights to file a Risperdal lawsuit.
Risperdal® is a registered trademark of Johnson & Johnson, and is used here only to identify the product in question.
This law firm is not associated with, sponsored by, or affiliated with Bloomberg L.P.; Johnson & Johnson; the Journal of Clinical Psychopharmacology; the National Center for Biotechnology Information; or the U.S. Food and Drug Administration.